澳大利亚老年人肺炎球菌疫苗接种率:PCV13全面公共资助前后对比
研究分析澳大利亚全科诊所192,508名65岁及以上常规就诊者数据,比较2020年7月1日PCV13全面资助政策实施前后PCV13和PPV23接种率变化。结果显示70岁及以上人群PCV13累积接种率上升,但65-69岁人群仍很低(合并症者3%),PPV23月接种率在所有年龄组下降。
要点
- 2020年7月1日澳大利亚将老年人免费肺炎球菌疫苗从65岁PPV23改为70岁PCV13。
- 截至2021年5月,70-79岁无合并症者PCV13累积接种率16.3%,有合并症者21.1%。
- 65-69岁人群PCV13累积接种率仍很低:无合并症1.3%,有合并症3%。
核心结论
- 70岁及以上人群PCV13和PPV23接种率变化与项目调整一致,但65-69岁整体及合并症患者PCV13接种率仍显著偏低。
研究设计与样本
- 分析全国全科诊所患者记录数据集,纳入2020年65岁及以上常规就诊者192,508名(2020年平均年龄75.1岁,女性54.2%,至少一种合并症者46.1%)。
- 比较项目变更前(2019年1月至2020年6月)与变更后(2020年7月至2021年5月)PCV13累积接种率和PPV23月接种率,按年龄组和合并症分层。
主要发现
- 2020年7月前所有成人无论有无合并症PCV13累积接种率均<1%。
- 截至2021年5月,70-79岁无合并症者PCV13累积接种率16.3%,有合并症者21.1%;80岁及以上无合并症者13.5%,有合并症者17.7%。
- 65-69岁无合并症者PCV13累积接种率1.3%,有合并症者3%。
- 项目变更后PPV23月接种率在所有年龄组均下降。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2020 Australia changed the funded universal older adult pneumococcal vaccination program from use of the 23-valent pneumococcal polysaccharide vaccine (PPV23) at age 65 to the 13-valent pneumococcal conjugate vaccine (PCV13) at age 70 years. We investigated uptake of both PCV13 and PPV23 in older adults before and after the program change. METHODS: We analysed a national dataset of records of patients attending general practices (GPs). We included regular attendees aged 65 or above in 2020. Cumulative uptake of PCV13 and monthly uptake of PPV23 was compared for the two periods before (January 2019 to June 2020) and after (July 2020 to May 2021) the program change on 1 July 2020, by age groups and presence of comorbid conditions. RESULTS: Our study included data from 192,508 patients (mean age in 2020: 75.1 years, 54.2 % female, 46.1 % with at least one comorbidity). Before July 2020, for all adults regardless of underlying comorbidities, the cumulative uptake of PCV13 was < 1 % but by May 2021, eleven months after the program changes, cumulative uptake of PCV13 had increased among those aged 70-79 years (without comorbidity: 16.3 %; with comorbidity: 21.1 %) and 80 + years (without comorbidity: 13.5 %; with comorbidity: 17.7 %), but not among those aged 65-69 years (without comorbidity: 1.3 %; with comorbidity: 3 %). Monthly uptake of PPV23 dropped following the program change across all age groups. CONCLUSIONS: Changes in uptake of PCV13 and PPV23 among those aged 70 + years were consistent with program changes. However, PCV13 uptake was still substantially lower in individuals aged 65-69 years overall and in those with comorbidities.
引用
- Binte Hossain F, Muscatello D, Jayasinghe S, et al. Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13. Vaccine. 2024. PMID: 38584056. doi:10.1016/j.vaccine.2024.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。